(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed its interim review of the Company’s ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (the “LDOS002 Study”). This review was not a formal analysis of data, but a review of safety and clinical parameters collected during the study to date.
- 0 Comments
- FY2014